Patent ID: 8293252

Claim:
A universal tumor vaccine composition that stimulates an immune response to autologous tumor cells in a patient when administered to said patient regardless of tumor type said composition comprising a mixture of two or more different allogeneic tumor cell lines wherein at least one-type of said allogeneic tumor cell lines comprises tumor stem cells, each of tumor cell lines natively secretes an immunosuppressive agent which is TGF-β, PGE-2 or CTLA-4 and has been genetically modified to inhibit the expression of said immunosuppressive agent, wherein the cell lines in said mixture collectively express tumor associated antigens such that of tumor-associated antigens representing all types tumor is presented, wherein said tumor type includes cancers of the colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, or other glandular tissue carcinomas or melanoma, cancer of the central nervous system or lymphoma.